Related Experiment Video
Updated: Dec 11, 2025

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
Adherence to a selective antenatal haemoglobinopathy screening policy within a tertiary level obstetric unit in
Ailsa Borbolla Foster1, Elloise Smith2, Bryony Ross3,4
1Department of Maternal Fetal Medicine, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
Insights
Selective antenatal screening for haemoglobinopathies (blood disorders) in Australia had an 83.7% failure rate. Universal screening is recommended to improve detection and ensure equitable care for all families.
Area of Science:
- Medical Genetics
- Public Health
- Obstetrics
Background:
- Haemoglobinopathies are the most common single-gene disorders globally.
- Antenatal screening practices for these disorders vary significantly between healthcare centers.
- Assessing screening policy performance is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the effectiveness of a selective antenatal screening policy for haemoglobinopathies in Australia.
- To determine the failure-to-screen rate among women with identifiable risk factors.
- To analyze maternal, paternal, prenatal, and neonatal testing outcomes.
Main Methods:
- A retrospective cohort study was conducted over two years.
- Identified women attending public antenatal care with at least one haemoglobinopathy risk factor.
- Collected data on screening rates, risk factors, and testing outcomes.
Main Results:
- A high overall failure-to-screen rate of 83.7% was observed.
- Screening was more frequent in multiparous women and those from the Middle East.
- Partner screening, when completed, reclassified 85.7% of offspring to low-risk.
Conclusions:
- The selective screening model demonstrated significant deficiencies in clinical utility and health equity.
- A high screen failure rate raises concerns about the current policy's effectiveness.
- Universal antenatal screening for haemoglobinopathies is recommended to enhance detection and counseling.
Background:
Haemoglobinopathies represent the most common single gene disorder worldwide; however, significant centre to centre variations in antenatal screening practices exist.
Aims:
To assess performance of a selective antenatal haemoglobinopathy screening policy within a presumed low-prevalence Australian population. Primary outcome was the failure to screen rate for women with at least one identifiable risk factor. Secondary outcomes included outcomes of maternal screening and rates, gestations and outcomes of paternal, prenatal and neonatal testing.
Materials And Methods:
A two-year retrospective cohort study identifying all women attending for public antenatal care with at least one identifiable risk factor for haemoglobinopathy.
Results:
At least one risk factor for haemoglobinopathy was identified in 8.8% of the entire pregnant cohort; however, the failure to screen rate was high at 83.7% overall. Screening was significantly more likely to be undertaken in multiparous women, those with multiple risk factors and women originating from the Middle East. Twenty percent of screened women returned an abnormal result; however, this led to paternal haemoglobinopathy screening in only 66.6%. Where completed, the addition of partner screening reclassified offspring to low-risk status in 85.7% of cases.
Conclusions:
This study demonstrates an 83.7% screen failure rate within a selective screening model raising concerns regarding the clinical utility and health equity of this approach. This major drawback of selective screening suggests that institution of a universal antenatal screening system for haemoglobinopathies, even in anticipated low-prevalence areas, will improve detection rates and ensure families receive appropriate and timely counselling.
More Related Videos
Related Concept Videos
Rh Blood Group
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...

